Skip to content
The Policy VaultThe Policy Vault

Tygacil (tigecycline) — CareFirst (Caremark)

Complicated intra-abdominal infections caused by susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros

Initial criteria

  • Patient age ≥ 18 years
  • Indicated infection proven or strongly suspected to be caused by susceptible bacteria
  • Tygacil should not be used for diabetic foot infections
  • Tygacil should not be used for hospital-acquired or ventilator-associated pneumonia
  • Appropriate cultures obtained to isolate and identify organisms and determine susceptibility
  • Use of Tygacil should be limited to treatment of infections proven or strongly suspected to be due to susceptible bacteria